Differential response to stem cell factor and flt3 ligand by the FAB subtype in acute myeloid leukemia clonogenic cells

Journal of Interferon and Cytokine Research

Volumn 22, Issue 3, 2002, Pages 335-341

  Murohashi, Ikuo ^a   Yoshida, Katsuhiko ^a   Kishimoto, Kuniya ^a   Takahashi, Takashi ^a   Wakao, Daisuke ^a   Jinnai, Itsuro ^b   Yagasaki, Fumiharu ^a   Kawai, Nobutaka ^a   Suzuki, Toshiya ^a   Matsuda, Akira ^a   Hirashima, Kunitake ^a   Bessho, Masami ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FLT3 LIGAND PROTEIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 3; MEMBRANE PROTEIN; RECOMBINANT PROTEIN; STEM CELL FACTOR; TUMOR NECROSIS FACTOR ALPHA; FLT3 LIGAND;

ACUTE DISEASE; ARTICLE; BLAST CELL CRISIS; CELL CLONE; CELL CULTURE; CELL DIVISION; CHRONIC MYELOID LEUKEMIA; COMPARATIVE STUDY; DRUG EFFECT; HUMAN; MYELOID LEUKEMIA; MYELOMONOCYTIC LEUKEMIA; PATHOLOGY; RETROSPECTIVE STUDY; ACUTE GRANULOCYTIC LEUKEMIA; AUTOCRINE EFFECT; BLAST CELL; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; HUMAN CELL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS;

ACUTE DISEASE; BLAST CRISIS; CELL DIVISION; CLONE CELLS; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERLEUKIN-3; LEUKEMIA, MYELOID; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, MYELOMONOCYTIC, ACUTE; MEMBRANE PROTEINS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; STEM CELL FACTOR; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA; COMPARATIVE STUDY; HUMAN; SUPPORT, NON-U.S. GOV'T; TUMOR NECROSIS FACTOR;

EID: 0036013762     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/107999002753675767     Document Type: Article

References (37)

1. Clonal development, stem cell differentiation, and clinical remission in acute nonlymphocytic leukemia
2. Proposed revised criteria for the classification of acute myeloid leukaemia
3. Molecular genetics in acute leukemia
4. Chronic myelocytic leukemia: Clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage
5. Regulatory mechanisms in stem cell biology
6. Proliferative state of blast cell progenitors in acute myeloblastic leukemia (AML)
7. The proliferation in suspension of the progenitors of the blast cells in acute myeloblastic leukemia
8. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell
9. Autocrine growth mechanisms of the progenitors of blast cells in acute myeloblastic leukemia
10. Growth potentiating activity of endogenous production of interleukin-1 and tumor necrosis factor-α in blast cells of acute myeloblastic leukemia
11. Roles of stem cell factor in the in vitro growth of blast clonogenic cells from patients with acute myeloblastic leukemia
12. c-kit ligand and flt3 ligand: Stem/progenitor cell factors with overlapping yet distinct activities
13. Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells
14. Effects of human FLT3 ligand on myeloid leukemia cell growth: Heterogeneity in response and synergy with other hematopoietic growth factors
15. Blasts from patients with acute myelogenous leukemia express functional receptors for stem cell factor
16. Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells
17. The product of the proto-oncogene c-kit (P145c-kit) is a human bone marrow surface antigen of hematopoietic precursor cells which is expressed on a subset of acute nonlymphoblastic leukemic cells
18. Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemia
19. The reliability and specificity of c-kit for the diagnosis of acute myeloid leukemias and undifferentiated leukemias
20. Effects of human stem cell factor (c-kit) on proliferation of myeloid leukemia cells: Heterogeneity in response and synergy with other hematopoietic growth factors
21. Expression of the c-kit receptor (CD117) is a feature of almost all subtypes ofde novo acute myeloblastic leukemia (AML), including cytogenetically good-risk AML, and lacks prognostic significance
22. Chronic myelogenous leukemia in no lymphoid blastic phase: Analysis of the results of first salvage therapy with three different treatment approaches for 162 patients
23. Allogenic bone marrow transplantation for acute nonlymphocytic leukemia in first remission
24. Acute myeloid leukaemia expressing the leukocyte integrin CD11b - A new leukaemic syndrome with poor prognosis: Result of an ECOG database analysis
25. Acute erythroid leukemia (M6): Outcome of bone marrow transplantation
26. All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia
27. Proliferative effects of several hematopoietic growth factors on acute myelogenous leukemia cells and correlation with treatment outcome
28. Autonomous proliferation of leukemic cellsin vitro as a determinant of prognosis in adult acute myeloid leukemia
29. + progenitor cells isolated from human bone marrow are functionally distinct
30. Primitive acute myeloid leukemia cells with long-term proliferative activity in vitro and in vivo lack surface expression of c-kit (CD117)
31. Acute non-lymphocytic leukemia: Heterogeneity of stem cell origin
32. A conditionally activated form of MEK1 results in autocrine transformation of human and mouse hematopoietic cells
33. Tumor necrosis factor alpha stimulates the growth of the clonogenic cells of acute myeloblastic leukemia in synergy with granulocyte/macrophage colony-stimulating factor
34. Phosphatydylcholine-specific phospholipase C and phospholipase D are respectively implicated in mitogen-activated protein kinase and nuclear factor kappa B activation in tumor necrosis factor-alpha-treated immature acute myeloid leukaemia cells
35. The generation of dendritic-like cells with increased allostimulatory function from acute myeloid leukemia cells of various FAB subclasses
36. Leukemic dendritic cells generated in the presence of FLT3 ligand have the capacity to stimulate an autologous leukemia-specific cytotoxic T cell response from patients with acute myeloid leukemia
37. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting-Airlie House, Virginia, November 1997